Inside the FDA’s Peptides Meeting: A Clinician’s Key Takeaways
On July 23 and 24, the Food and Drug Administration’s Pharmacy Compounding Advisory Committee (PCAC) met to consider whether a set of peptides should be added to the 503A Bulks List, which would permit licensed compounding pharmacies to legally make these drugs by physician prescription. In a reversal of the committee’s past stance, PCAC voted […]




